{"id":153293,"date":"2014-11-03T00:00:00","date_gmt":"2014-11-03T00:00:00","guid":{"rendered":"https:\/\/v2.optiknow.ca\/excellent-troisieme-trimestre-pour-valeant\/"},"modified":"2014-11-03T00:00:00","modified_gmt":"2014-11-03T00:00:00","slug":"excellent-troisieme-trimestre-pour-valeant","status":"publish","type":"post","link":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/","title":{"rendered":"Excellent troisi\u00e8me trimestre pour Valeant"},"content":{"rendered":"<p>La pharmaceutique qu\u00e9b\u00e9coise Valeant, propri\u00e9taire notamment de Bausch + Lomb, enregistre son deuxi\u00e8me meilleur trimestre depuis sa cr\u00e9ation en 1960.<\/p>\n<p>L'entreprise d\u00e9clare des revenus de 2,36\u00a0milliards CAD au 3e trimestre de 2014, comparativement \u00e0 1,69 milliard\u00a0CAD pour la m\u00eame p\u00e9riode en 2013. Mais c'est surtout du c\u00f4t\u00e9 des profits que le changement est drastique, Valeant affichant un profit de 309,5\u00a0millions CAD au troisi\u00e8me trimestre de 2014, alors qu'elle pr\u00e9sentait des pertes de 1,09\u00a0milliard CAD \u00e0 la m\u00eame \u00e9poque en 2013.<\/p>\n<p>Le chiffre d'affaires de Valeant dans les lentilles corn\u00e9ennes a bondi de 82\u00a0% en un an. Au total, la croissance organique de Bausch + Lomb s'est \u00e9lev\u00e9e \u00e0 12\u00a0%.<\/p>\n<p>Valeant soutient que ces bons r\u00e9sultats d\u00e9montrent la qualit\u00e9 de son mod\u00e8le d'affaires, une allusion directe aux attaques d'Allergan. Depuis que Valeant tente d'acqu\u00e9rir Allergan, cette derni\u00e8re n'a de cesse de d\u00e9crier sur la place publique le mod\u00e8le d'affaires de Valeant. Allergan avait m\u00eame mis en ligne, juste avant la publication des r\u00e9sultats de Valeant, un document d'une trentaine de pages, d\u00e9crivant les points sur lesquels les investisseurs devraient \u00e9valuer la performance de la pharmaceutique. Le document a \u00e9t\u00e9 retir\u00e9 depuis.<\/p>\n<p>Le PDG de Valeant, Michael Pearson, a d\u00e9clar\u00e9 en t\u00e9l\u00e9conf\u00e9rence que \u00ab\u00a0nous venons de d\u00e9montrer par notre performance que toutes les all\u00e9gations d'Allergan sont fausses\u00a0\u00bb, rapporte La Presse. Du m\u00eame souffle, il a soutenu \u00eatre pr\u00eat \u00e0 s'assoir avec les dirigeants d'Allergan, afin de bonifier l'offre de rachat hostile, pr\u00e9sentement \u00e9valu\u00e9e \u00e0 environ 50\u00a0milliards CAD.<\/p>\n<p>&nbsp;<\/p>\n<p>Sources : <a title=\"Excellent troisi\u00e8me trimestre pour Valeant\" href=\"http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2014\/Valeant-Pharmaceuticals-Reports-Third-Quarter-2014-Financial-Results\/default.aspx\" target=\"_blank\">http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2014\/Valeant-Pharmaceuticals-Reports-Third-Quarter-2014-Financial-Results\/default.aspx<\/a><\/p>\n<p><a title=\"Excellent troisi\u00e8me trimestre pour Valeant\" href=\"http:\/\/affaires.lapresse.ca\/resultats-financiers\/201410\/20\/01-4810785-valeant-disposee-a-modifier-son-offre-sur-allergan.php\" target=\"_blank\">http:\/\/affaires.lapresse.ca\/resultats-financiers\/201410\/20\/01-4810785-valeant-disposee-a-modifier-son-offre-sur-allergan.php<\/a><\/p>\n<p><a title=\"Excellent troisi\u00e8me trimestre pour Valeant\" href=\"http:\/\/www.visionmonday.com\/business\/financial\/article\/valeant-pharmaceuticals-reports-revenue-increase-for-q3-1\/\" target=\"_blank\">http:\/\/www.visionmonday.com\/business\/financial\/article\/valeant-pharmaceuticals-reports-revenue-increase-for-q3-1\/<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La pharmaceutique qu\u00e9b\u00e9coise Valeant, propri\u00e9taire notamment de Bausch + Lomb, enregistre son deuxi\u00e8me meilleur trimestre depuis sa cr\u00e9ation en 1960.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23135],"tags":[],"class_list":["post-153293","post","type-post","status-publish","format-standard","hentry","category-nouvelles-financieres"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Excellent troisi\u00e8me trimestre pour Valeant - OptikNow<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Excellent troisi\u00e8me trimestre pour Valeant - OptikNow\" \/>\n<meta property=\"og:description\" content=\"La pharmaceutique qu\u00e9b\u00e9coise Valeant, propri\u00e9taire notamment de Bausch + Lomb, enregistre son deuxi\u00e8me meilleur trimestre depuis sa cr\u00e9ation en 1960.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/\" \/>\n<meta property=\"og:site_name\" content=\"OptikNow\" \/>\n<meta property=\"article:published_time\" content=\"2014-11-03T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Optiknow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Optiknow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/\"},\"author\":{\"name\":\"Optiknow\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\"},\"headline\":\"Excellent troisi\u00e8me trimestre pour Valeant\",\"datePublished\":\"2014-11-03T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/\"},\"wordCount\":317,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"articleSection\":[\"Nouvelles financi\u00e8res\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/\",\"name\":\"Excellent troisi\u00e8me trimestre pour Valeant - OptikNow\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\"},\"datePublished\":\"2014-11-03T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/11\\\/03\\\/excellent-troisieme-trimestre-pour-valeant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Excellent troisi\u00e8me trimestre pour Valeant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"name\":\"OptikNow\",\"description\":\"Canadian Eye Care and Eyewear News for Eye Care Professionals\",\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\",\"name\":\"OptikNow\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"width\":1181,\"height\":250,\"caption\":\"OptikNow\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\",\"name\":\"Optiknow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"caption\":\"Optiknow\"},\"sameAs\":[\"https:\\\/\\\/v2.optiknow.ca\"],\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/author\\\/optiknow\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Excellent troisi\u00e8me trimestre pour Valeant - OptikNow","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Excellent troisi\u00e8me trimestre pour Valeant - OptikNow","og_description":"La pharmaceutique qu\u00e9b\u00e9coise Valeant, propri\u00e9taire notamment de Bausch + Lomb, enregistre son deuxi\u00e8me meilleur trimestre depuis sa cr\u00e9ation en 1960.","og_url":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/","og_site_name":"OptikNow","article_published_time":"2014-11-03T00:00:00+00:00","author":"Optiknow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Optiknow","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/#article","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/"},"author":{"name":"Optiknow","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150"},"headline":"Excellent troisi\u00e8me trimestre pour Valeant","datePublished":"2014-11-03T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/"},"wordCount":317,"commentCount":0,"publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"articleSection":["Nouvelles financi\u00e8res"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/","url":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/","name":"Excellent troisi\u00e8me trimestre pour Valeant - OptikNow","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#website"},"datePublished":"2014-11-03T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/11\/03\/excellent-troisieme-trimestre-pour-valeant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v2.optiknow.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Excellent troisi\u00e8me trimestre pour Valeant"}]},{"@type":"WebSite","@id":"https:\/\/v2.optiknow.ca\/fr\/#website","url":"https:\/\/v2.optiknow.ca\/fr\/","name":"OptikNow","description":"Canadian Eye Care and Eyewear News for Eye Care Professionals","publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v2.optiknow.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/v2.optiknow.ca\/fr\/#organization","name":"OptikNow","url":"https:\/\/v2.optiknow.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","width":1181,"height":250,"caption":"OptikNow"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150","name":"Optiknow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","caption":"Optiknow"},"sameAs":["https:\/\/v2.optiknow.ca"],"url":"https:\/\/v2.optiknow.ca\/fr\/author\/optiknow\/"}]}},"_links":{"self":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/comments?post=153293"}],"version-history":[{"count":0,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153293\/revisions"}],"wp:attachment":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media?parent=153293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/categories?post=153293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/tags?post=153293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}